Literature DB >> 6902727

Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.

L Halbwachs, M Leveillé, P Lesavre, S Wattel, J Leibowitch.   

Abstract

A factor, functionally characterized by its capacity to stabilize the normally labile classical pathway C3-converting complex of the classical pathway of complement, has been isolated from the serum of one patient with a case of acute glomerulonephritis, subsequent to a cutaneous infection. The factor confers long-lived stabilization of classical pathway C3 convertase complexes formed both in the solid (sensitized sheep erythrocytes bearing activated C1 and the classical pathway C3 convertase) and fluid phase. The half-life of such stabilized C3-cleaving enzymes extended beyond several hours at 37 degrees C. The stabilizing activity was associated with a protein fraction immunochemically identified as immunoglobulin (Ig)G, a sizeable population of which exhibited a gamma chain of 60,000 daltons. The IgG-associated stabilizing activity was found to bind to the classical pathway C3 convertase enzyme via a fragment bearing the antigen-binding site of the molecule [F(ab)(2) and F(ab)]. Such binding was demonstrable for classical pathway and not for alternative pathway C3 convertase. Thus, the stabilizing factor behaves like an autoantibody to the C3-converting complex of the classical pathway of complement. The binding of the antibody to the enzyme affords protection of the latter against decay-degradation. By analogy with the nephritic factor of the alternative pathway situation where IgG autoantibodies specifically bind to alternative pathway C3 convertase enzymes and protect them from degradation, the functionally unusual IgG in our patient was designated as the nephritic factor of the classical pathway. Indirect evidence suggests that nephritic factor of the classical pathway-IgG might be of the IgG3 subclass.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6902727      PMCID: PMC371461          DOI: 10.1172/jci109787

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS.

Authors:  C B LAURELL
Journal:  Anal Biochem       Date:  1965-02       Impact factor: 3.365

2.  Rheumatoid factor, complement, and conglutinin aberrations in patients with subacute bacterial endocarditis.

Authors:  R C WILLIAMS; H G KUNKEL
Journal:  J Clin Invest       Date:  1962-03       Impact factor: 14.808

3.  The immunogloblin nature of nephritic factor (NeF).

Authors:  D M Scott; N Amos; J G Sissons; P J Lachmann; D K Peters
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

4.  Isolation of normal human IgG3. Identical molecular weight for normal and monoclonal gamma-3 chains.

Authors:  C C Patrick; G Virella
Journal:  Immunochemistry       Date:  1978-02

5.  The purification and properties of the second component of human complement.

Authors:  M A Kerr; R R Porter
Journal:  Biochem J       Date:  1978-04-01       Impact factor: 3.857

6.  The activation of the C3b feedback cycle with human complement components. I. Through the classical pathway.

Authors:  L W Mak; P J Lachmann; J Majewski
Journal:  Clin Exp Immunol       Date:  1977-11       Impact factor: 4.330

7.  [Description of an unusual enzymic activity cleaving the third component of complement].

Authors:  J Leibowitch; M Leveille; L Halbwachs
Journal:  C R Seances Acad Sci D       Date:  1979-02-05

8.  The alternative pathway C3/C5 convertase: chemical basis of factor B activation.

Authors:  P H Lesavre; T E Hugli; A F Esser; H J Müller-Eberhard
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

9.  Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.

Authors:  H J Müller-Eberhard; M J Polley; M A Calcott
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

10.  Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator.

Authors:  T Fujita; I Gigli; V Nussenzweig
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

View more
  31 in total

Review 1.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

2.  Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor.

Authors:  M R Daha; L A Van Es
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

Review 3.  Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.

Authors:  Andrew S Bomback; Gerald B Appel
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

4.  C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.

Authors:  Yuzhou Zhang; Nicole C Meyer; Fernando C Fervenza; Winnie Lau; Adam Keenan; Gabriel Cara-Fuentes; Dingwu Shao; Aalia Akber; Veronique Fremeaux-Bacchi; Sanjeev Sethi; Carla M Nester; Richard J H Smith
Journal:  Am J Kidney Dis       Date:  2017-08-24       Impact factor: 8.860

5.  Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A van Es
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

Review 6.  Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.

Authors:  Y Levy; J George; E Yona; Y Shoenfeld
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

7.  Autoantibody to the C3b/C4b receptor and absence of this receptor from erythrocytes of a patient with systemic lupus erythematosus.

Authors:  J G Wilson; R M Jack; W W Wong; P H Schur; D T Fearon
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

8.  Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN).

Authors:  H Ohi; T Yasugi
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

9.  C3 nephritic factor and hypocomplementaemia in a clinically healthy individual.

Authors:  A T Gewurz; S M Imherr; S Strauss; H Gewurz; C Mold
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

Review 10.  Idiopathic membranoproliferative glomerulonephritis in childhood.

Authors:  C D West
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.